Regularly monitor the patient’s clinical response. Look for improvements in symptoms such as fever reduction, decreased cough severity, and resolution of other infection signs within 2-3 days of starting Augmentin.
Closely track any adverse effects. Amoxicillin-clavulanate, the active ingredient in Augmentin, can cause diarrhea, nausea, vomiting, and rash. Report any significant or persistent side effects immediately.
Perform complete blood counts (CBCs) and liver function tests (LFTs) before initiating Augmentin therapy and periodically thereafter, especially for patients on prolonged treatment or with pre-existing hepatic or hematologic conditions. Monitor for abnormal results indicative of drug-related toxicity.
Assess renal function, especially in patients with impaired renal function. Dosage adjustments may be necessary based on creatinine clearance values.
Consider antibiotic susceptibility testing to confirm that Augmentin is the appropriate treatment choice for the identified infection. This is especially important for recurrent or persistent infections.
Monitor for signs of pseudomembranous colitis, a serious complication that can occur with antibiotic use. Diarrhea accompanied by abdominal cramping and fever should be investigated promptly.
For patients with penicillin allergies, carefully assess the risk versus benefits of Augmentin use. Alternatives may be preferable.
Educate patients on recognizing and reporting side effects. Patient education significantly improves treatment compliance and safety.
